Acylcarnitines are derived from mitochondrial acyl-coenzyme A (CoA) metabolism, and the accumulation of acylcarnitines can interfere with insulin signaling in type II diabetes [33, 34] and thus may be associated with higher risks of impaired glucose tolerance and type II diabetes in IUGR. The gene discussed is INS; the disease is fetal growth restriction.